| Identification | Back Directory | [Name]
Teplizumab | [CAS]
876387-05-2 | [Synonyms]
Teplizumab
Teplizumab (DHC27703)
Teplizumab (anti-CD3e)
Research Grade Teplizumab(DHC27703)
TeplizumabQ: What is
Teplizumab Q: What is the CAS Number of
Teplizumab |
| Hazard Information | Back Directory | [Uses]
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes[1][2]. | [in vivo]
Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice[2].
| Animal Model: | NOD/SCID IL2γc-/- (NSG) mice (a tolergenic humanized mouse model)[1] | | Dosage: | 0.24 mg/kg, 5 μg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05.
Decreased circulating hCD4 cells in the peripheral blood.
Decreased in the proportion of T cells in the bone marrow and lung.
Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.
|
| [References]
[1] Kevan C Herold, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613. DOI:10.1056/NEJMoa1902226
[2] Frank Waldron-Lynch, et al. I Analysis of FcR non-binding anti-CD3 mAb in humanized mice identifies novel human gut tropic cells with regulatory function that are found in patients. Sci Transl Med. 2012 Jan 25;4(118):118ra12. DOI:10.1126/scitranslmed.3003401
[3] Brygida Bisikirska, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct;115(10):2904-13. DOI:10.1172/JCI23961 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|